MAPT and Alzheimer disease: Although Aβ and tau accumulations seemed to be a hallmark of AD for decades, even the most advanced and promising pharmacological strategies directed to reduce Aβ load failed so far to demonstrate consistent cognitive improvements in AD patients (cf. Ref.